MeiraGTx Holdings Gelecekteki Büyüme

Future kriter kontrolleri 5/6

MeiraGTx Holdings kazanç ve gelirinin sırasıyla yıllık 7.1% ve 46.8% oranında artması tahmin edilirken, EPS'nin yıllık 11.6% oranında büyümesi bekleniyor.

Anahtar bilgiler

7.1%

Kazanç büyüme oranı

11.6%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	46.8%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	13 Nov 2024

Gelecekteki son büyüme güncellemeleri

Analysts Have Lowered Expectations For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its Latest Results

Nov 15

Recent updates

Analysts Have Lowered Expectations For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its Latest Results

Nov 15

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

Oct 15

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

Jul 15

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Reducing Their Forecasts For This Year

Mar 16

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are More Bearish Than They Used To Be

Nov 16

MeiraGTx GAAP EPS of -$0.76, revenue of $10.76M

Aug 11

MeiraGTx inks $100M debt agreement backed by manufacturing facilities

Aug 03

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

Apr 29

Analysts' Revenue Estimates For MeiraGTx Holdings plc (NASDAQ:MGTX) Are Surging Higher

Mar 15

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:MGTX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	206	-89	N/A	N/A	2
12/31/2025	172	101	N/A	N/A	2
12/31/2024	13	-144	N/A	N/A	2
9/30/2024	14	-88	-103	-96	N/A
6/30/2024	8	-93	-105	-95	N/A
3/31/2024	11	-74	-118	-105	N/A
12/31/2023	14	-84	-126	-105	N/A
9/30/2023	7	-132	-133	-107	N/A
6/30/2023	6	-125	-135	-103	N/A
3/31/2023	14	-129	-143	-102	N/A
12/31/2022	16	-130	-118	-73	N/A
9/30/2022	42	-112	-99	-38	N/A
6/30/2022	44	-101	-97	-34	N/A
3/31/2022	39	-87	-82	-28	N/A
12/31/2021	38	-80	-57	-11	N/A
9/30/2021	20	-80	-91	-59	N/A
6/30/2021	19	-61	-77	-51	N/A
3/31/2021	16	-66	-66	-42	N/A
12/31/2020	16	-58	-87	-64	N/A
9/30/2020	19	-53	-74	-56	N/A
6/30/2020	17	-57	-79	-66	N/A
3/31/2020	17	-52	-86	-75	N/A
12/31/2019	13	-55	11	20	N/A
9/30/2019	6	-70	17	31	N/A
6/30/2019	3	-75	26	38	N/A
3/31/2019	1	-86	30	41	N/A
12/31/2018	N/A	-85	-70	-59	N/A
9/30/2018	N/A	-73	-56	-51	N/A
6/30/2018	N/A	-66	N/A	-44	N/A
3/31/2018	N/A	-42	N/A	-29	N/A
12/31/2017	N/A	-32	N/A	-18	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MGTX önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: MGTX önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: MGTX önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: MGTX şirketinin gelirinin (yıllık 46.8% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MGTX şirketinin gelirinin (yıllık 46.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MGTX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

MeiraGTx Holdings Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Analysts Have Lowered Expectations For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its Latest Results

Price target increased by 7.3% to US$22.75

Consensus revenue estimates fall by 35%

Price target increased by 40% to US$21.20

Price target decreased by 19% to US$17.50

Consensus revenue estimates decrease by 11%, EPS upgraded

Recent updates

Analysts Have Lowered Expectations For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its Latest Results

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.3% to US$22.75

MeiraGTx Holdings plc Announces Positive Data from Randomized, Sham-Controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

Consensus revenue estimates fall by 35%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

MeiraGTx Holdings plc has completed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 40% to US$21.20

Price target decreased by 19% to US$17.50

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

MeiraGTx Holdings (NASDAQ:MGTX) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates decrease by 11%, EPS upgraded

First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.62 loss in 1Q 2023)

MeiraGTx Holdings plc, Annual General Meeting, Jun 06, 2024

MeiraGTx Holdings plc Appoints Dr. Debra Yu to Serve on Each of the Compensation Committee and Science and Technology Committee of the Board

Price target decreased by 10.0% to US$21.60

New major risk - Financial position

MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met

CEO, President & Director exercised options and sold US$101k worth of stock

CEO, President & Director exercised options and sold US$587k worth of stock

Forecast to breakeven in 2025

MeiraGTx Holdings plc has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MeiraGTx Holdings plc announced that it has received $30 million in funding from Sanofi Foreign Participations B.V.

New minor risk - Share price stability

MeiraGTx Holdings plc Announces an Oral Presentation and Eight Posters At the European Society of Gene and Cell Therapy 2023 Annual Congress

Does MeiraGTx Holdings (NASDAQ:MGTX) Have A Healthy Balance Sheet?

Consensus revenue estimates decrease by 12%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MeiraGTx Holdings plc Announces Positive Clinical Data from the AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx Holdings plc to Present 12-Month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MeiraGTx Holdings plc announced that it expects to receive $61.525 million in funding from Perceptive Advisors LLC, 683 Capital Management, LLC, Prosight Management, LP, Adage Capital Management, L.P.

Calculating The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX)

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Reducing Their Forecasts For This Year

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 7.4% to US$31.00

CEO, President & Director exercised options and sold US$222k worth of stock

CEO, President & Director exercised options and sold US$170k worth of stock

MeiraGTx Holdings plc cAnnounces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Consensus revenue estimates fall by 26%

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are More Bearish Than They Used To Be

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

MeiraGTx Holdings plc announced that it has received $24.999994 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MeiraGTx GAAP EPS of -$0.76, revenue of $10.76M

MeiraGTx Holdings plc announced that it expects to receive $100 million in funding from Perceptive Advisors LLC

MeiraGTx Holdings plc announced that it expects to receive $100 million in funding from Perceptive Advisors LLC

MeiraGTx inks $100M debt agreement backed by manufacturing facilities

MeiraGTx Holdings plc Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients Treated with Botaretigene Sparoparvovec (AAV-RPGR) Compared to Untreated Randomized Control

Consensus forecasts updated

Price target decreased to US$30.57

MeiraGTx Holdings plc Presents Clinical Data on Botaretigene Sparoparvovec for Treatment of X-Linked Retinitis Pigmentosa at Association for Research in Vision and Ophthalmology 2022 Annual Meeting

MeiraGTx Holdings plc, Annual General Meeting, Jun 07, 2022

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

MeiraGTx Appoints Debra Yu to Board of Directors

Insufficient new directors

Insufficient new directors

Consensus revenue estimates increase by 28%

Analysts' Revenue Estimates For MeiraGTx Holdings plc (NASDAQ:MGTX) Are Surging Higher

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi